AR106543A1 - NTN1 NEUTRALIZING AGENT COMBINATION THERAPY WITH DRUGS THAT INHIBIT EPIGENTICAL CONTROL - Google Patents

NTN1 NEUTRALIZING AGENT COMBINATION THERAPY WITH DRUGS THAT INHIBIT EPIGENTICAL CONTROL

Info

Publication number
AR106543A1
AR106543A1 ARP160103327A ARP160103327A AR106543A1 AR 106543 A1 AR106543 A1 AR 106543A1 AR P160103327 A ARP160103327 A AR P160103327A AR P160103327 A ARP160103327 A AR P160103327A AR 106543 A1 AR106543 A1 AR 106543A1
Authority
AR
Argentina
Prior art keywords
ntn1
neutralizing agent
composition
inhibitor
netrin
Prior art date
Application number
ARP160103327A
Other languages
Spanish (es)
Original Assignee
Netris Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Netris Pharma filed Critical Netris Pharma
Publication of AR106543A1 publication Critical patent/AR106543A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

La composición farmacéutica o anticancerígena para el tratamiento de un cáncer que tiene una pérdida dependiente de la metilación de ADN, de la expresión de NTN1, UNC5H o DAPK1. Además se refiere a un método de tratamiento de dichos tipos de cáncer. La composición comprende un fármaco epigenético y un agente neutralizante de NTN1 o un vector capaz de expresar un agente neutralizante de NTN1 in vivo, en un portador o vehículo farmacéuticamente aceptable. El agente neutralizante de NTN1, tal como un anticuerpo que se une a netrina-1 o a un receptor de netrina-1, promueve la apoptosis inducida por receptores de netrina-1. El fármaco epigenético puede ser un inhibidor de ADN metiltransferasa o un inhibidor de HDAC. Reivindicación 1: Una composición farmacéutica que comprende un fármaco epigenético seleccionado de un inhibidor de la metilación de ADN y un inhibidor que tiene actividad inhibidora de histona, y un agente neutralizante de NTN1 o un vector capaz de expresar un agente neutralizante de NTN1 in vivo, en un portador o vehículo farmacéuticamente aceptable. Reivindicación 7: La composición de la reivindicación 6, donde el inhibidor de ADN metiltransferasa se selecciona del grupo que consiste en azacitidina; decitabina; zebularina; 5,6-dihidro-5-azacitidina; 5-fluoro-2’-desoxicitidina; NPEOC-DAC; CP-4200; y decitabina-p-desoxiguanosina (SGl-110), procainamida, procaína, hidralazina, (-)-epigalocatequin-3-galato (EGCG), N-ftalil-1-triptófano (RG108) y SGI-1027. Reivindicación 9: La composición de la reivindicación 8, donde el inhibidor de HDAC es un ácido hidroxámico o un péptido cíclico. Reivindicación 14: La composición para el uso de acuerdo con la reivindicación 11, 12 ó 13, que comprende el fármaco epigenético y el agente neutralizante de NTN1 o vector capaz de expresar un agente neutralizante de NTN1 in vivo, para una administración simultánea, separada o secuencial a un paciente.The pharmaceutical or anticancer composition for the treatment of a cancer that has a loss dependent on DNA methylation, on the expression of NTN1, UNC5H or DAPK1. It also refers to a method of treating such types of cancer. The composition comprises an epigenetic drug and an NTN1 neutralizing agent or a vector capable of expressing an NTN1 neutralizing agent in vivo, in a pharmaceutically acceptable carrier or vehicle. The NTN1 neutralizing agent, such as an antibody that binds to netrin-1 or a netrin-1 receptor, promotes apoptosis induced by netrin-1 receptors. The epigenetic drug can be a DNA methyltransferase inhibitor or an HDAC inhibitor. Claim 1: A pharmaceutical composition comprising an epigenetic drug selected from a DNA methylation inhibitor and an inhibitor having histone inhibitory activity, and an NTN1 neutralizing agent or a vector capable of expressing an NTN1 neutralizing agent in vivo, in a pharmaceutically acceptable carrier or vehicle. Claim 7: The composition of claim 6, wherein the DNA methyltransferase inhibitor is selected from the group consisting of azacitidine; decitabine; zebularin; 5,6-dihydro-5-azacitidine; 5-fluoro-2’-deoxycytidine; NPEOC-DAC; CP-4200; and decitabine-p-deoxyguanosine (SGl-110), procainamide, procaine, hydralazine, (-) - epigallocatequin-3-gallate (EGCG), N-phthalyl-1-tryptophan (RG108) and SGI-1027. Claim 9: The composition of claim 8, wherein the HDAC inhibitor is a hydroxamic acid or a cyclic peptide. Claim 14: The composition for use according to claim 11, 12 or 13, which comprises the epigenetic drug and the NTN1 neutralizing agent or vector capable of expressing an NTN1 neutralizing agent in vivo, for simultaneous, separate administration or sequential to a patient.

ARP160103327A 2015-11-02 2016-11-01 NTN1 NEUTRALIZING AGENT COMBINATION THERAPY WITH DRUGS THAT INHIBIT EPIGENTICAL CONTROL AR106543A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP15306743 2015-11-02

Publications (1)

Publication Number Publication Date
AR106543A1 true AR106543A1 (en) 2018-01-24

Family

ID=54478684

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103327A AR106543A1 (en) 2015-11-02 2016-11-01 NTN1 NEUTRALIZING AGENT COMBINATION THERAPY WITH DRUGS THAT INHIBIT EPIGENTICAL CONTROL

Country Status (3)

Country Link
AR (1) AR106543A1 (en)
TW (1) TW201720459A (en)
WO (1) WO2017076864A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112574990A (en) * 2020-12-11 2021-03-30 武汉大学 shRNA molecule for silencing human DAPK1 gene expression and application thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69120146T2 (en) 1990-01-12 1996-12-12 Cell Genesys Inc GENERATION OF XENOGENIC ANTIBODIES
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
ES2136092T3 (en) 1991-09-23 1999-11-16 Medical Res Council PROCEDURES FOR THE PRODUCTION OF HUMANIZED ANTIBODIES.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
ES2304786T3 (en) 1995-04-27 2008-10-16 Amgen Fremont Inc. ANTI-IL-8 HUMAN ANTIBODIES, DERIVED FROM IMMUNIZED XENORATONES.
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DK1500329T3 (en) 1996-12-03 2012-07-09 Amgen Fremont Inc Human antibodies that specifically bind TNF-alpha
WO1998046645A2 (en) 1997-04-14 1998-10-22 Micromet Gesellschaft Für Biomedizinische Forschung Mbh Method for the production of antihuman antigen receptors and uses thereof
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6613753B2 (en) 2001-02-21 2003-09-02 Supergen, Inc. Restore cancer-suppressing functions to neoplastic cells through DNA hypomethylation
ES2601352T3 (en) 2006-02-28 2017-02-14 Centre National De La Recherche Scientifique (Cnrs) Screening for anti-cancer compounds using netrin-1 activity
EP2050764A1 (en) 2007-10-15 2009-04-22 sanofi-aventis Novel polyvalent bispecific antibody format and uses thereof
EP2307002B1 (en) * 2008-06-09 2013-01-02 Cyclacel Limited Combinations of sapacitabine or cndac with dna methyltransferase inhibitors such as decitabine and procaine
CN103339507A (en) 2010-08-26 2013-10-02 霍夫曼-拉罗奇有限公司 Recombinant Fc-fusion protein of the fifth fibronectin type iii domain of DCC
EP2708231A1 (en) 2012-09-12 2014-03-19 Netris Pharma Combined treatment with netrin-1 interfering drug and chemotherapeutic drug
EP2893939A1 (en) 2014-01-10 2015-07-15 Netris Pharma Anti-netrin-1 antibody

Also Published As

Publication number Publication date
WO2017076864A1 (en) 2017-05-11
TW201720459A (en) 2017-06-16

Similar Documents

Publication Publication Date Title
BR212016030926U2 (en) target conjugates and particles and formulations thereof
CL2023000846A1 (en) Combination therapy including krasg12c inhibitor and pharmaceutically active agent to treat cancer
BR112017018318A2 (en) A pharmaceutical composition for treating cancer comprising a micro RNA as an active ingredient
BR112018003316A2 (en) compounds and methods for transmembrane delivery of molecules
BR112018003985A2 (en) peptidomimetic macrocycles and their uses
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
BR112017013597A2 (en) nucleic acid molecule, pharmaceutical composition, vector or cell, and method for treating a disease.
NZ730296A (en) Modified double-stranded rna agents
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
BR112019021822A2 (en) COMBINATION THERAPY
BR112019004322A2 (en) glucocorticoid receptor modulators to treat pancreatic cancer
EA201890272A1 (en) AXL-SPECIFIC CONJUGATES ANTIBODY AND MEDICINE FOR THE TREATMENT OF CANCER
EA201790674A1 (en) CYTOTOXIC INDUCING THERAPEUTIC AGENT
BR112016022553A2 (en) COMPOUNDS AND METHODS FOR TRANSMEMBRANE DELIVERY OF MOLECULES?
BR112013026494A2 (en) compound, pharmaceutical composition, method for treating condition
CL2013003105A1 (en) Microarn compounds comprising modified nucleoside sequences, mir-21 inhibitors; uses of the compounds to modulate the activity of mir -21 and to prepare a drug to treat fibrosis, wounds or cancer
BR112013005872A2 (en) compounds, pharmaceutical composition and their uses
PE20150722A1 (en) MODULATORS OF THE EXPRESSION OF ANDROGENIC RECEPTORS THAT INCLUDE A MODIFIED OLIGONUCLEOTIDE
BR112017025698A2 (en) compositions and methods for inhibiting hif2alpha gene expression
BR112012029975A2 (en) peptide as a medicine, in particular for the treatment of cancer.
BR112017027985A2 (en) therapeutic peptides and methods of use thereof
BR112018001292A2 (en) methods for better release of active agents to tumors
CY1122968T1 (en) PHARMACEUTICAL COMPOSITION CONTAINING A DIAMINO-HETEROCYCLIC CARBOXAMIDE COMPOUND AS AN ACTIVE INGREDIENT
AR081209A1 (en) TREATMENT OF DISEASES RELATED TO PROTEIN 11 OF TYPE LYMPHOMA 2 OF CELLS B, (BCL2, BCL2L11) BY INHIBITION OF THE NATURAL ANTISENTIDE TRANSCRIPT TO BCL2L11
BR112018001435A2 (en) methods for lymphatic delivery of active agents

Legal Events

Date Code Title Description
FB Suspension of granting procedure